Subclinical hyperthyroidism: a special comorbidity factor in patients with Parkinson’s disease

Related Articles:

• Subclinical hyperthyroidism: a special comorbidity factor in patients with Parkinson's disease January 24, 2023 Pharmacol Rep. 2023 Jan 25. doi: 10.1007/s43440-023-00449-5. Online ahead of print.NO ABSTRACTPMID:36694030 | DOI:10.1007/s43440-023-00449-5
• Subclinical hyperthyroidism: a special comorbidity factor in patients with Parkinson's disease January 24, 2023 Pharmacol Rep. 2023 Jan 25. doi: 10.1007/s43440-023-00449-5. Online ahead of print.NO ABSTRACTPMID:36694030 | DOI:10.1007/s43440-023-00449-5
• Subclinical hyperthyroidism: a special comorbidity factor in patients with Parkinson's disease January 24, 2023 Pharmacol Rep. 2023 Jan 25. doi: 10.1007/s43440-023-00449-5. Online ahead of print.NO ABSTRACTPMID:36694030 | DOI:10.1007/s43440-023-00449-5
• Subclinical hyperthyroidism: a special comorbidity factor in patients with Parkinson's disease January 24, 2023 Pharmacol Rep. 2023 Jan 25. doi: 10.1007/s43440-023-00449-5. Online ahead of print.NO ABSTRACTPMID:36694030 | DOI:10.1007/s43440-023-00449-5
• Parkinson’s and Autoimmunity January 26, 2023 “I am always doing that which I cannot do, in order that I may learn how to do it.” Pablo Picasso “We have more possibilities available in each moment than we realize.” Nhat Hanh Précis: This post exists because I received a note from a reader concerned about using a substance that potentially was an immune enhancer, coupled with the…
• Thyroid Dysfunction and Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis May 23, 2022 Front Endocrinol (Lausanne). 2022 May 4;13:863281. doi: 10.3389/fendo.2022.863281. eCollection 2022.ABSTRACTOBJECTIVE: Studies have suggested that patients with thyroid dysfunction may have an increased risk of developing Parkinson's disease (PD). However, the results from existing studies are inconsistent. Therefore, we aimed to investigate the association of hypothyroidism and hyperthyroidism with risk of PD using the method of systematic review and meta-analysis.METHODS: Potentially…
• Thyroid Dysfunction and Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis May 23, 2022 Front Endocrinol (Lausanne). 2022 May 4;13:863281. doi: 10.3389/fendo.2022.863281. eCollection 2022.ABSTRACTOBJECTIVE: Studies have suggested that patients with thyroid dysfunction may have an increased risk of developing Parkinson's disease (PD). However, the results from existing studies are inconsistent. Therefore, we aimed to investigate the association of hypothyroidism and hyperthyroidism with risk of PD using the method of systematic review and meta-analysis.METHODS: Potentially…
• Thyroid Dysfunction and Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis May 23, 2022 Front Endocrinol (Lausanne). 2022 May 4;13:863281. doi: 10.3389/fendo.2022.863281. eCollection 2022.ABSTRACTOBJECTIVE: Studies have suggested that patients with thyroid dysfunction may have an increased risk of developing Parkinson's disease (PD). However, the results from existing studies are inconsistent. Therefore, we aimed to investigate the association of hypothyroidism and hyperthyroidism with risk of PD using the method of systematic review and meta-analysis.METHODS: Potentially…
• A nod to immunomod with fingolimod October 16, 2022 # # # # In general, your immune system does a truly amazing job of keeping you healthy and the dangerous pathogenic world around us at bay. Trillions of cells constantly monitoring for viruses and other illness-causing agents, and ruthlessly disposing of any that they actually find. But sometimes your immune system can get a little carried away with this…
• Monthly Research Review – September 2022 September 30, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during September 2022. The post is divided into 10 parts based on the type of research: Top 6 pieces of Parkinson’s news Articles of general interest Basic biology…
• Association of subclinical atherosclerosis and cognitive decline: a community-based cross-sectional study May 25, 2022 BMJ Open. 2022 May 24;12(5):e059024. doi: 10.1136/bmjopen-2021-059024.ABSTRACTBACKGROUND AND AIMS: Growing burden of dementia was considered as a global public health priority as its epidemic scale rises with the world's population increases in age. In the absence of effective treatment, early identification of decline in cognitive function and risk factors that lead to the onset of dementia is a critical issue.…
• Association of subclinical atherosclerosis and cognitive decline: a community-based cross-sectional study May 25, 2022 BMJ Open. 2022 May 24;12(5):e059024. doi: 10.1136/bmjopen-2021-059024.ABSTRACTBACKGROUND AND AIMS: Growing burden of dementia was considered as a global public health priority as its epidemic scale rises with the world's population increases in age. In the absence of effective treatment, early identification of decline in cognitive function and risk factors that lead to the onset of dementia is a critical issue.…
• Association of subclinical atherosclerosis and cognitive decline: a community-based cross-sectional study May 25, 2022 BMJ Open. 2022 May 24;12(5):e059024. doi: 10.1136/bmjopen-2021-059024.ABSTRACTBACKGROUND AND AIMS: Growing burden of dementia was considered as a global public health priority as its epidemic scale rises with the world's population increases in age. In the absence of effective treatment, early identification of decline in cognitive function and risk factors that lead to the onset of dementia is a critical issue.…
• Association of subclinical atherosclerosis and cognitive decline: a community-based cross-sectional study May 25, 2022 BMJ Open. 2022 May 24;12(5):e059024. doi: 10.1136/bmjopen-2021-059024.ABSTRACTBACKGROUND AND AIMS: Growing burden of dementia was considered as a global public health priority as its epidemic scale rises with the world's population increases in age. In the absence of effective treatment, early identification of decline in cognitive function and risk factors that lead to the onset of dementia is a critical issue.…
• Association of subclinical atherosclerosis and cognitive decline: a community-based cross-sectional study May 25, 2022 BMJ Open. 2022 May 24;12(5):e059024. doi: 10.1136/bmjopen-2021-059024.ABSTRACTBACKGROUND AND AIMS: Growing burden of dementia was considered as a global public health priority as its epidemic scale rises with the world's population increases in age. In the absence of effective treatment, early identification of decline in cognitive function and risk factors that lead to the onset of dementia is a critical issue.…
• 10 Lessons Learned About COVID-19 and Parkinson’s January 8, 2023 “Come grow old with me. The best is yet to be.” William Wordsworth “As long as I am breathing, in my eyes, I am just beginning.” Criss Jami Introduction:  Likely, everyone in the world has said the words “COVID-19 Pandemic” at some point since early 2020. From mid-February 2020 to December 2022, more than 324,000 publications on some aspects of COVID-19…
• Motion characteristics of subclinical tremors in Parkinson's disease and normal subjects March 8, 2022 Sci Rep. 2022 Mar 7;12(1):4021. doi: 10.1038/s41598-022-07957-z.ABSTRACTThe characteristics of the Parkinson's disease tremor reported previously are not applicable to the full spectrum of severity. The characteristics of high- and low-amplitude tremors differ in signal regularity and frequency dispersion, a phenomenon that indicates characterisation should be studied separately based on the severity. The subclinical tremor of Parkinson's disease is close to…
• Motion characteristics of subclinical tremors in Parkinson's disease and normal subjects March 8, 2022 Sci Rep. 2022 Mar 7;12(1):4021. doi: 10.1038/s41598-022-07957-z.ABSTRACTThe characteristics of the Parkinson's disease tremor reported previously are not applicable to the full spectrum of severity. The characteristics of high- and low-amplitude tremors differ in signal regularity and frequency dispersion, a phenomenon that indicates characterisation should be studied separately based on the severity. The subclinical tremor of Parkinson's disease is close to…
• Motion characteristics of subclinical tremors in Parkinson's disease and normal subjects March 8, 2022 Sci Rep. 2022 Mar 7;12(1):4021. doi: 10.1038/s41598-022-07957-z.ABSTRACTThe characteristics of the Parkinson's disease tremor reported previously are not applicable to the full spectrum of severity. The characteristics of high- and low-amplitude tremors differ in signal regularity and frequency dispersion, a phenomenon that indicates characterisation should be studied separately based on the severity. The subclinical tremor of Parkinson's disease is close to…
• Motion characteristics of subclinical tremors in Parkinson's disease and normal subjects March 8, 2022 Sci Rep. 2022 Mar 7;12(1):4021. doi: 10.1038/s41598-022-07957-z.ABSTRACTThe characteristics of the Parkinson's disease tremor reported previously are not applicable to the full spectrum of severity. The characteristics of high- and low-amplitude tremors differ in signal regularity and frequency dispersion, a phenomenon that indicates characterisation should be studied separately based on the severity. The subclinical tremor of Parkinson's disease is close to…
• GSK-3β-mediated regulation of Nrf2/HO-1 signaling as a new therapeutic approach in the treatment of movement disorders July 26, 2022 Pharmacol Rep. 2022 Jul 26. doi: 10.1007/s43440-022-00390-z. Online ahead of print.ABSTRACTMovement disorders are neurological conditions characterized by involuntary motor movements, such as dystonia, ataxia, chorea myoclonus, tremors, Huntington's disease (HD), and Parkinson's disease (PD). It is classified into two categories: hypokinetic and hyperkinetic movements. Globally, movement disorders are a major cause of death. The pathophysiological process is initiated by excessive…
• Allosteric modulation of dopamine D2L receptor in complex with Gi1 and Gi2 proteins: the effect of subtle structural and stereochemical ligand modifications January 22, 2022 Pharmacol Rep. 2022 Jan 22. doi: 10.1007/s43440-021-00352-x. Online ahead of print.ABSTRACTBACKGROUND: Allosteric modulation of G protein-coupled receptors (GPCRs) is nowadays one of the hot topics in drug discovery. In particular, allosteric modulators of D2 receptor have been proposed as potential modern therapeutics to treat schizophrenia and Parkinson's disease.METHODS: To address some subtle structural and stereochemical aspects of allosteric modulation of…